Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease.
Roblin, Xavier, Stéphane Nancey, Konstantinos Papamichael, Gérard Duru, Mathurin Flamand, Sandy Kwiatek, Adam Cheifetz, Nicole Fabien, Mathilde Barrau, and Stephane Paul. 2024. “Higher Serum Infliximab Concentrations Following Subcutaneous Dosing Are Associated With Deep Remission in Patients With Inflammatory Bowel Disease.”. Journal of Crohn’s & Colitis 18 (5): 679-85.